The caveolae-endocytosis inhibitor, genistein45, significantly reduced CAV1, HER3 and NBP uptake in HBMVECs (Fig. 4f and Supplementary Fig. 27) but not in human HER3+ tumour cells (Supplementary Fig. S27). This evidence concerns the gene CAV1 and neoplasm.